What the evidence reports on tolerability, adverse events, and contraindications across the incretin class — including muscle-preservation and dose-management considerations. Not medical advice; always consult a licensed clinician.
A patient with a BMI of 38 initiates semaglutide 0.25 mg/week (Wegovy) and advances on calendar schedule at week 4 to 0.5 mg. Nausea begins on day 2 of the new dose. At week 8, the prescriber…
The Patient Who Stopped Too Soon A 47-year-old woman, 214 lbs at peak, had worked down to 171 lbs over 14 months on semaglutide 2.4 mg weekly. She felt great. Her physician agreed she could take a…
The Problem Nobody Warned Their Patients About A 54-year-old woman comes back for her 12-week semaglutide check-in. She's down 22 pounds. Her physician is thrilled. But when you pull up her DEXA…
What the evidence and FDA prescribing information report on GLP-1 side effects, how GI symptoms are managed, and long-term safety data. Not medical advice.